Bibliography
- Davidson A, Diamond B. Autoimmune diseases. New Engl J Med 2001;345(5):340-50
- Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005;345(7042):612-9
- Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003;2(3):119-25
- Ermann J, Fathman CG. Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2001;2(9):759-61
- Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001;7(8):899-905
- Steinman L. Immune therapy for autoimmune diseases. Science 2004;305(5681):212-6
- Mouzaki A, Tselios T, Papathanassopoulos P, et al. Immunotherapy for multiple sclerosis: basic insights for new clinical strategies. Curr Neurovasc Res 2004;1(4):325-40
- Zamvil SS, Steinman L. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 2003;38(5):685-8
- Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004;5(6):575-81
- Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45(7):926-33
- Doyle HA, Mamula MJ. Posttranslational protein modifications: new flavours in the menu of autoantigens. Curr Opin Rheumatol 2002;14(3):244-9
- Yamada R, Suzuki A, Chang X, Yamamoto K. Peptidylarginine deiminase type 4: identification of a rheumatoid arthritis-susceptible gene. Trends Mol Med 2003;9(11):503-8
- Gyorgy B, Toth E, Tarcsa E, et al. Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006;38(10):1662-77
- Chavanas S, Mechin MC, Takahara H, et al. Comparative analysis of the mouse and human peptidylarginine deiminase gene cluster reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 2004;330:19-27
- Vossenaar ER, Zendman AJ, Van Venrooij WJ, et al. A growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003;25(11):1106-18
- Tarcsa E, Marekov LN, Mei G, et al. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996;271(48):30709-16
- Chatzantoni K, Mouzaki A. Anti-TNF-α antibody therapies in autoimmune diseases. Curr Top Med Chem 2006;6(16):1707-14
- Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1(8542):1108-11
- Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27(2):269-81
- Sekine T, Masuko-Hongo K, Matsui T, et al. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60(1):49-54
- Tsuruha J, Masuko-Hongo K, Kato T, et al. Implication of cartilage intermediate layer protein in cartilage destruction in subsets of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2001;44(4):838-45
- Kim WU, Cho ML, Jung YO, et al. Type II collagen autoimmunity in rheumatoid arthritis. Am J Med Sci 2004;327(4):202-11
- Iwaki-Egawa S, Matsuno H, Yudoh K, et al. High diagnostic value of anticalpastatin autoantibodies in rheumatoid arthritis detected by ELISA using human erythrocyte calpastatin as antigen. J Rheumatol 2004;31(1):17-22
- Van Boekel MA, Vossenaar ER, Van Den Hoogen FH, Van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4(2):87-93
- Schellekens GA, De Jong BA, Van Den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101(1):273-81
- Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162(1):585-94
- Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166(6):4177-84
- Vossenaar ER, Despres N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6(2):R142-50
- Pratesi F, Tommasi C, Anzilotti C, et al. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anticitrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54(3):733-41
- Matsuo K, Xiang Y, Nakamura H, et al. Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res Ther 2006;8(6):R175
- Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34(4):395-402
- Lundberg K, Nijenhuis S, Vossenaar ER, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005;7(3):R458-67
- Hill JA, Southwood S, Sette A, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171(2):538-41
- Schellekens GA, Visser H, De Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43(1):155-63
- Knuckley B, Luo Y, Thomson PR. Profiling protein arginine deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem 2008;16(2):739-45
- Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-26
- Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006;103:9685-90
- Imamura T, Matsushita K, Travis J, Potempa J. Inhibition of trypsin-like cysteine proteinases (gingipains) from Porphyromonas gingivalis by tetracycline and its analogues. Antimicrob Agents Chemother 2001;45:2871-76
- Luo Y, Knuckley B, Lee Y, et al. A fluoroacetamide-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc 2006;128(4):1092-3
- Luo Y, Arita K, Bhatia M, et al. Inhibitors and inactivators of protein arginine deiminase 4: Functional and structural characterization. Biochemistry 2006;45(39):11727-36
- Mouzaki A, Deraos S, Chatzantoni K. Advances in the treatment of autoimmune diseases; cellular activity, type-1/type-2 cytokine secretion patterns and their modulation by therapeutic peptides. Curr Med Chem 2005;12(50):1537-50
- Musse AA, Harauz G. Molecular negativity may underlie multiple sclerosis: Role of the myelin basic protein family in the pathogenesis of MS. Int Rev Neurobiol 2007;79:149-72
- Musse AA, Boggs JM, Harauz G. Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad sci USA 2006;103(12):4422-7
- Balandraud N, Gouret P, Danchin EG, et al. A rigorous method for multigenic families' functional annotation: the peptidyl arginine deiminase (PADs) proteins family example. BMC Genomics 2005;6:153
- Moscarello MA, Wood DD, Ackerley C, Boulias C. Myelin in multiple sclerosis is developmentally immature. J Clin Invest 1994;94(1):146-54
- Wood DD, Bilbao JM, O'Connors P, Moscarello MA. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996;40(1):18-24
- Moscarello MA, Pritzker L, Mastronardi FG, Wood DD. Peptidylarginine deiminase: a candidate factor in demyelinating disease. J Neurochem 2002;81(2):335-43
- Pritzker LB, Moscarello MA. A novel microtubule independent effect of paclitaxel: the inhibition of peptidylarginine deiminase from bovine brain. Biochim Biophys Acta 1998;1388(1):154-60
- Moscarello MA, Mak B, Nguyen TA, et al. Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination. Mult Scler 2002;8(2):130-8
- Cao L, Sun D, Whitaker JN. Citrullinated myelin basic protein induces experimental autoimmune encephalomyelitis in Lewis rats through a diverse T cell repertoire. J Neuroimmunol 1998;88:21-9
- Nicholas AP, Sambandam T, Echols JD, Barnum SR. Expression of citrullinated proteins in murine experimental autoimmune encephalomyelitis. J Comp Neurol 2005;486:254-66
- Raijmakers R, Vogelzangs J, Croxford JL, et al. Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. J Comp Neurol 2005;486:243-53
- Raijmakers R, Vogelzangs J, Raats J, et al. Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J Comp Neurol 2006;498:217-26
- Chatenoud L. Emerging therapies for autoimmune diseases. In: Rose NR, Mackay IR, editors, The autoimmune diseases. Elsevier: Amsterdam-Tokyo; 2006
- Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature 2005;435(7042):620-7
- Burt RK, Marmont AM. Stem cell therapy for autoimmune disease. Landes Bioscience, Georgetown: USA; 2006
- Muraro P, Douek DC. Renewing the T cell repertoire to arrest immune aggression. Trends Immunol 2006;27:61-7
- Marmont AM, Gualandi F, Occhini D, et al. Catastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal haemolytic-uremic syndrome. Autoimmunity 2006;39:505-11
- Brodsky RA, Petri M, Smith BD, et al. Immunablative high dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease. Ann Intern Med 1998;129(12):1031-5
- Marmont AM. Will hematopoietic stem cell transplantation cure human autoimmune diseases? J Autoimmun 2008;30(3):145-50
- Burt RK, Traynor AE, Craig R, Marmont AM. The promise of hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2003;31(7):521-4
- Burt RK, Padilla J, Begolka WS, et al. Effect of disease stage on outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998;97(7):2609-16
- Van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol 2000;20(1):10-6
- Tyndall A, Fassas A, Passweg J, et al. Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease. Bone Marrow Transplant 1999;24(7):729-34
- Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000;28(7):853-7
- Hinterberger W, Hinterberger-Fischer M, Marmont AM. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcomes after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant 2002;30(11):753-9
- Nash RA, MC Sweeney P, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term followup of the US multicenter study. Blood 2007;110(4):1388-96
- Burt RK, Marmont AM, Oyama Y, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases. The evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006;54(12):3750-60
- Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplan 2005;35(9):869-79
- Schiffenbauer J, Hahn B, Weisman MH, Simon LS. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum 2004;50(8):2415-22
- Mckendry RJ, Huebsch L, Leclair B. Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year follow up. Arthritis Rheum 1996;39(7):1246-53
- Snowden JA, Kearney P, Kearney A, et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum 1998;41(3):453-9
- Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002;73(9):1386-91
- Burt RK, Oyama Y, Verda L, et al. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis Rheum 2004;50(8):2466-70
- Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998;92:1471-90
- Brodsky RA. High-dose cyclophosphamide for aplastic anemia and autoimmunity. Curr Opin Oncol 2002;14:143-6
- Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 2004;126:637-49
- Hough RE, Snowden JA, Wulffraat NM. Haematopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol 2005;128:432-59
- Tyndall A, Saccardi R. Hematopoietic stem cell transplantation in the treatment of severe autoimmune disease – results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol 2005;141(1):1-9
- Mouzaki A, Theodoropoulou M, Gianakopoulos I, et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment; their role in prognosis. Blood 2002;100(5):1774-9
- Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002;109:131-40
- Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 2007;3(11):619-26
- Eggleton P, Haigh R, Winyard PG. Consequence of neo-antigenicity of the ‘altered self’. Rheumatology 2008;47(5):567-71